Eculizumab reversed severe distal ischemic syndrome and glomerulonephritis with isolated C3 deposits associated with anti-factor H autoantibodies: a case report - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue Clinical Rheumatology Année : 2018

Eculizumab reversed severe distal ischemic syndrome and glomerulonephritis with isolated C3 deposits associated with anti-factor H autoantibodies: a case report

Résumé

B-cell clones can produce a monoclonal immunoglobulin, which may be responsible for visceral involvements. Kidney involvement is frequent, affecting 20 to 50% of patients with multiple myeloma. One mechanism underlying this involvement is a dysregulation of the complement alternative pathway, leading to C3 glomerulopathies. We report a patient who had a multiple myeloma, C3 glomerulopathy related to factor H autoantibody, and digital ischemia, who was treated successfully with eculizumab, an anti-complement therapy, without any relapse in 2 years of follow-up.
Fichier non déposé

Dates et versions

hal-01838458 , version 1 (13-07-2018)

Identifiants

Citer

Samuel Deshayes, Nicolas Martin Silva, Valérie Châtelet, Sylvain Chantepie, Moglie Le Quintrec, et al.. Eculizumab reversed severe distal ischemic syndrome and glomerulonephritis with isolated C3 deposits associated with anti-factor H autoantibodies: a case report. Clinical Rheumatology, 2018, 37 (4), pp.1119 - 1122. ⟨10.1007/s10067-018-4058-6⟩. ⟨hal-01838458⟩
52 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More